MoonLake Immunotherapeutics (MLTX) vs Seaport Therapeutics (SPTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Seaport Therapeutics is the larger company by market cap ($968.1 million vs $922.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLTX | SPTX |
|---|---|---|
| Share price | $10.84 | $18.09 |
| Market cap | $922.56M | $968.10M |
| 1-day change | +2.46% | +0.98% |
| YTD return | -19.73% | — |
| 1-year return | +16.26% | — |
| 5-year return | +6.65% | — |
| EPS (TTM) | $-3.83 | $-5.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.29 | $28.38 |
| 52-week low | $8.80 | $14.85 |
| Distance from 52-week high | -53.46% | -36.28% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +163.28% | +111.72% |
| Average volume | 1.47M | 182.45K |
| Shares outstanding | 85.11M | 53.53M |
| Employees | 130 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
About Seaport Therapeutics
SPTX stock →Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
MLTX vs SPTX FAQ
Which is bigger, MoonLake Immunotherapeutics or Seaport Therapeutics?
Seaport Therapeutics (SPTX) is larger, with a market capitalization of $968.10M compared with $922.56M for MoonLake Immunotherapeutics (MLTX).
Are MoonLake Immunotherapeutics and Seaport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.